Search the Newsreel

E.W. Scripps Co (SSP) executive discloses RSU and share holdings

Kevin D. Littleton, President, Media of E.W. Scripps Co, has reported his initial beneficial ownership in the company. He directly holds 48,558 Class A Common Shares and also has restricted stock unit awards totaling 224,604 shares which are scheduled to vest between 2027 and …

AMG Critical Materials (ENXTAM:AMG) Stock Looks Near Fair Value After 35% Gain

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. AMG Critical Materials stock has returned 35.0% over the past year, and after that …

Neurocrine Biosciences (NBIX) CSO Jude Onyia makes bona fide stock gift

Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences (NBIX), made a bona fide gift of 2,409 shares of common stock effective August 4, 2026. This transaction was a charitable contribution, not a market sale, and no value was received for the shares. After this …

Criteo (NASDAQ: CRTO) sets cross-border merger into U.S. holding company

Criteo S.A. (NASDAQ: CRTO) is planning a cross-border merger into its wholly-owned U.S. subsidiary, Criteo Holdings, Inc., which will result in a one-for-one share exchange for shareholders. The merger is expected to be effective on January 1, 2027, and is contingent upon shareholder approval, …

Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discount

Neurocrine Biosciences (NBIX) is presented as a compelling value stock due to its strong valuation score, profitability, and growth prospects despite trading at a higher-than-average P/E. The company boasts excellent financial health, a debt-free balance sheet, and impressive historical and projected EPS and revenue …

Criteo Sa earnings beat by $0.10, revenue topped estimates

Criteo Sa (NASDAQ: CRTO) reported second-quarter EPS of $0.80, surpassing analyst estimates by $0.10. The company's revenue for the quarter was $428 million, significantly exceeding the consensus estimate of $263.51 million. Despite a 6.55% decrease over the last 12 months, the stock has risen …

Criteo Releases Q2 2026 Financial Results

Criteo S.A. reported strong Q2 2026 financial results, exceeding Wall Street expectations with adjusted earnings of $0.80 per share against an estimated $0.69, and revenue reaching $428.0M compared to a $263.4M consensus. Despite a year-over-year revenue decline, the company demonstrated successful cost management, achieving …

Acrivon advances cancer drug ACR-2316 to dose expansion phase

Acrivon Therapeutics Inc. (NASDAQ:ACRV) has advanced its experimental cancer drug ACR-2316 to the randomized dose expansion phase of its Phase 1/2 study, selecting 120 mg and 160 mg oral doses. This decision follows successful dose escalation in 35 subjects, where the WEE1/PKMYT1 inhibitor showed …

Criteo Q2 Earnings Call Highlights

Key Points Interested in Criteo S.A.? Here are five stocks we like better. Criteo lowered its 2026 outlook after second-quarter results missed expectations, primarily because several large Performance Media clients reduced spending. Full-year Contribution ex-TAC is now expected to decline 10% to 12% at …

Cricut (NASDAQ:CRCT) Sees Unusually-High Trading Volume After Earnings Beat

Crinetics Pharmaceuticals (CRNX) Stock Lags As Revenue Builds And Losses Deepen

Crinetics Pharmaceuticals (CRNX) has shown significant revenue growth, with Q2 2026 revenue reaching US$25.1 million, largely due to scaling product sales like PALSONIFY. Despite this, the company's net losses have deepened, reporting a US$120.9 million quarterly loss and a US$501.6 million trailing 12-month loss. …

Cricut, Inc. (NASDAQ:CRCT) Receives Consensus Rating of "Strong Sell" from Brokerages

Breaking News about Cricut, Inc. - Class A common stock (Nasdaq:CRCT)

This article provides recent news and financial updates concerning Cricut, Inc. (NASDAQ:CRCT), including its Q2 2026 earnings beat, Q1 2026 earnings transcript, and mixed Q4 results with profitability gains. It also lists several scheduled earnings dates and mentions Cricut in various stock analyses and …

Strata Critical Medical (SRTA) Stock Faces Clinical Progress And Lingering Losses

Strata Critical Medical (SRTA) reported Q2 2026 results showing significant clinical revenue growth, reaching US$72.5m, and improved adjusted EBITDA margins, signaling a successful pivot towards clinical services. Despite these operational improvements and positive free cash flow, the company continues to face losses, a short …

CRITEO REPORTS SECOND QUARTER 2026 RESULTS

Criteo S.A. reported disappointing financial results for the second quarter of 2026, with revenue decreasing by 11% and net income by 49% year-over-year. Despite the decline, the company remains confident in its Commerce Intelligence strategy, appointing Connor McGogney as CFO and expanding its Retail …

Should Value Investors Buy Carter's (CRI) Stock?

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends …

Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Crispr Therapeutics AG (CRSP) with a price target of $110.00. This follows similar Buy ratings from William Blair, though Morgan Stanley maintained a Hold. The company recently reported Q2 revenue of $10.18 million and …

Acrivon Therapeutics (ACRV) Projected to Post Earnings on Wednesday

Acrivon Reports 3 Lung Cancer Subjects on Treatment for Over a Year

Acrivon Therapeutics announced that its drug candidate, ACR-2316, a WEE1/PKMYT1 inhibitor, has advanced to randomized dose expansion in its Phase 1/2 study. This progression is based on a favorable safety profile and observed clinical activity, including tumor shrinkage and partial responses, with three lung …

Strata Critical Medical, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:SRTA)

This article provides the slide deck published by Strata Critical Medical, Inc. (SRTA) in conjunction with their Q2 2026 earnings call. The content is presented by SA Transcripts, a team dedicated to publishing earnings call transcripts and related developments.

Strata Critical Medical, Inc. 2Q 2026: Revenue $72.51M, EPS ($0.12) — 10-Q Summary

Strata Critical Medical, Inc. reported its Q2 2026 financial results, showing revenue of $72.51 million, a 60.7% increase year-over-year, largely due to Logistics expansion and newly acquired Clinical services. The net loss widened to ($10.52M) with a diluted loss per share of ($0.12). The …

Criteo S.A. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CRTO) 2026-08-05

Criteo S.A. published its Q2 2026 earnings call presentation, detailing financial results. The company reported an EPS of $0.80, beating estimates by $0.11, but revenue of $255.47M missed expectations by $7.95M, representing a 12.53% year-over-year decrease. The slide deck accompanies their recent earnings call.

Critical Resources (ASX:CRR) Rises as Mavis Lake Adds Land and New Targets

Cricut Delivers Higher Profits Amid Declining Quarterly Revenue

Criteo (CRTO) Earnings Date and Reports 2026 $CRTO

Criteo (Nasdaq: CRTO) Q2 2026 earnings fall as media segments soften

Cricut earnings beat by $0.14, revenue fell short of estimates

Criteo sinks as weak outlook overshadows earnings beat (CRTO:NASDAQ)

Top Metal and Mining Stocks to Watch: Why Is Critical Resources (ASX:CRR) Under the Spotlight?

Cricut, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CRCT) 2026-08-05

Cricut, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Platform Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. …

Cricut (CRCT) Stock Jumps As One Off Gains Cloud Profit Surge

Cricut (CRCT) saw its stock jump 23% after reporting Q2 net income of US$39.1m on US$156.3m revenue, largely due to tariff refunds and a royalty settlement. While the profit surge makes the company's valuation look appealing, questions remain about the sustainability of these gains, …

Crispr Earnings: Casgevy Gains Traction as Commercial Hurdles Begin to Ease

Crizac makes Q1FY27 earnings call audio available for investor review

Strata Critical Medical Inc (SRTA) (Q2 2026) Earnings Call Highlights: Revenue Surges 60. ...

Strata Critical Medical Inc (SRTA) reported a 60.7% year-over-year revenue increase to $72.5 million in Q2 2026, driven by strong clinical revenue growth and strategic acquisitions. The company raised its full-year 2026 revenue and adjusted EBITDA guidance, citing outperformance in its base business and …

Earnings call transcript: Cricut tops EPS forecast in Q2 2026 as revenue slips

CRISPR Therapeutics AG Stock 12‑Month Price Target Raised to $84.39, Implies 70% Upside

The average 12-month price target for CRISPR Therapeutics AG (CRSP) stock has been raised to $84.39 from $83.94, based on estimates from 18 analysts. This updated target implies a potential upside of approximately 70% from its Aug. 3 closing price. The consensus rating among …